A process is disclosed for treating cancer by the process of indirect targeted immunocytolysis, which comprises conjugating an immunogenic sensitizing agent to a targeting agent which is capable of binding to aberrant cells, such as cancer cells in a human or animal host. The conjugate is then introduced into the body of an animal or human which has previously been actively immunized against the sensitizing agent or concomitantly treated with the appropriate antibody (passive immunization). Binding of the conjugate to the object cells occurs and is accompanied by the binding of antibodies produced against the sensitizing agent. This results in triggering of a complement cascade and/or an antibody-dependent T-cell-mediated response leading to cell destruction. Also disclosed are the novel targeting agent/sensitizing agent conjugates for use in the process. Agents comprise autocrine differentiation-inhibiting factor/toxoid conjugates.
申请公布号
US5378815(A)
申请公布日期
1995.01.03
申请号
US19920872966
申请日期
1992.02.10
申请人
NATIONAL RESEARCH COUNCIL CANADA;CONSEL NATIONAL DE RECHERCHE SCIENTIFIQUE
发明人
KRSMANOVIC, VELIBOR;DURKIN, JON P.;BHASIN, JAGMOHAN L.;BIQUARD, JEAN-MICHEL;MACDONALD, PHILLIP A.;WHITFIELD, JAMES F.